No Bones About It: $35M Add Helps Drive Thrasos' AKI Drug
By Randy Osborne
Thursday, October 25, 2012
The ripe market for an acute kidney injury (AKI) therapy good enough to win FDA approval drew Thrasos Therapeutics Inc. into the game, and $35 million in funding should help the company through Phase II trials with THR-184, its lead compound.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.